

POLYPODIUM LEUCOTOMOS EXTRACT: A NUTRACEUTICAL WITH PHOTOPROTECTIVE PROPERTIES

Salvador Gonzalez^{1,2}, José Luis Alonso-Lebrero³, Rosa Del Rio⁴ and Pedro Jaen^{2,4}

¹Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA,

²Dermatology Service, Ramon y Cajal Hospital, Alcalá University, Madrid, Spain, ³R&D Department, Industrial Farmaceutica Cantabria S.A., Madrid, Spain, and ⁴Grupo de Dermatología, Madrid, Spain

CONTENTS

| | |
|---|--|
| Summary..... | |
| Introduction..... | |
| The need for photoprotection: Effect of UV radiation on skin | |
| <i>P. leucotomos</i> : Molecular composition and pharmacology..... | |
| Evidence for the photoprotective effect of <i>P. leucotomos</i> | |
| Molecular basis of photoprotection..... | |
| Conclusions | |
| References | |

Summary

Ultraviolet (UV) irradiation causes multifaceted damage to the skin and adjacent tissue layers, and is one of the leading causes of premature skin aging, immunosuppression and carcinogenesis. Photoprotection can be achieved by the use of sunscreens and also by systemically administered compounds that fight the deleterious biological effects of UV exposure, or preferably both. In this review, we summarize the current knowledge on the tissue, cellular and molecular mechanisms underlying the photoprotective effect of *Polypodium leucotomos* fern extract. *P. leucotomos* blocked the

deleterious effect of UV irradiation both *in vivo* and *in vitro*. The molecular basis of photoprotection relies on its ability to inhibit free radical generation, prevent photodecomposition of both endogenous photoprotective molecules and DNA, and prevent UV-induced cell death. Its complete loss of toxicity combined with its multifactor protection makes it a valuable tool not only for direct photoprotection, but also as an efficacious adjuvant to phototherapy of various skin diseases. © 2007 Prous Science. All rights reserved.

Introduction

The search for natural compounds with beneficial properties is as old as research itself. This search was focused on mitigating or preventing the deleterious effects of different diseases or external aggressions. Among these, sunburn is one of the

Correspondence: Salvador Gonzalez, Memorial Sloan-Kettering Cancer Center, 160 East 53rd St., New York, NY, 10022 USA. Tel.: +1 212 610 0185; Fax: +1 212 308 0530; E-mail: gonzals6@mskcc.org

most obvious manifestations of aggression from natural sources. Sunburn causes inflammation, pain and itching, and has long-term deleterious effects, including skin cancer.

Indigenous tribes from Central and South America have used different plant extracts as part of their folk medicine to alleviate the symptoms of inflammatory diseases of the skin. Among these, *Polypodium leucotomos* (from the Greek *poly* meaning *many* and *podia* meaning *little feet*, based on the foot-like appearance of the rhizome and branches) is a tropical fern plant of the *Polypodiaceae* family (1). It is native to the plateaus of the Andes range in South America and elevated (700–2,500 meters) areas of Central America, including Honduras and Guatemala. It was first introduced in Europe after the return of the botanical expedition of Ruiz, organized and funded by the Spanish Crown (2). *P. leucotomos* has long been known to possess beneficial properties for the skin (3). However, direct application of the plant itself in cases of psoriasis and atopic dermatitis yields scarcely significant results, probably due to a low concentration of the active principle(s) involved in its beneficial effect. More recently, a purified hydrophilic extract of the leaves of *P. leucotomos* has been shown to reduce skin sensitivity to damaging UV radiation and to possess a wide array of beneficial effects in the prevention of sunburn and related processes.

In this review, we summarize our current knowledge on the composition, pharmacological properties and reported effects of *P. leucotomos*, focusing on the molecular mechanisms involved in photoprotection from UV light.

The need for photoprotection: Effect of UV radiation on skin

Ultraviolet (UV) radiation forms part of the electromagnetic spectrum, including wavelengths between 200 nm and 400 nm (4). It is usually divided into three further components, UVA (320–400 nm), UVB (280–320 nm) and UVC (200–280 nm). UVC, the most energetic of the UV light spectrum, is also the most harmful for the skin, but it is completely absorbed by ozone in the stratosphere. In fact, no wavelengths under 290 nm reach the Earth's surface (5). UV exposure of the skin has a number of biological effects, most of them detrimental (Table I). These include the following:

i. Local generation of reactive oxygen species (ROS) and other deleterious metabolites.

Exposure of the skin to UV radiation results in generation of reactive oxygen species (6, 7). ROS are normally removed by cellular antioxidant systems, which prevent the deleterious effects of ROS and establish a pro-oxidant/antioxidant balance. Chronic exposure to elevated levels of UV light causes accumulation of an excess of free radicals that results in a cascade of events leading to deterioration of cellular integrity and function due to DNA damage and aberrant gene expression (see below), which leads to tumor formation and premature aging. ROS damages cell membranes by peroxidation of fatty acids that constitute the inner structure of the membrane, and it generates lipid peroxide radicals, lipid hydroperoxides and other byproducts that amplify and perpetuate oxida-

Table I: Deleterious effects of UV light on the skin.

| | Mediator | Short-term effects | Long-term effects |
|---|--|---------------------------------|---------------------------------------|
| Generation of free radicals | ROS, RNS | | Photoaging, cancer, immunosuppression |
| Generation of other deleterious metabolites | UCA photoisomerization, <i>t</i> -photodecomposition | | Photoaging, immunosuppression |
| Inflammation | Cell death, apoptosis | Sunburn erythema, pain, itching | Photoaging, cancer |
| DNA damage | Pyrimidine dimers (mainly thymine-thymine) and pyrimidine-pyrimidone | | Tumorigenesis, cancer |
| Immunosuppression | Depletion of eLC | Susceptibility to infection | Chronic inflammatory diseases, cancer |

ROS = reactive oxygen species; RNS = reactive nitrogen species; UCA = urocanic acid; eLC = epidermal Langerhans cells.

tive damage (6). Other deleterious metabolites induced by UV light include *cis*-urocanic acid (*c*-UCA), which appears as a product of UV-induced photoisomerization of *trans*-urocanic acid (*t*-UCA). *t*-UCA is produced by deamination of the amino acid histidine and is a photoprotective molecule occurring naturally in the skin, due to its ability to absorb UV photons (8). *c*-UCA has been involved in immunosuppression due, at least partially, to its effect on epidermal Langerhans cells (9), and also induces abnormal mast-cell degranulation (10).

- ii. **Inflammation.** UV-induced erythema is a process, due to increased blood flow and vasodilation (11), in which nitric oxide and prostaglandins are key players (12, 13). UV irradiation also induces sunburn of keratinocytes and underlying fibroblasts, which is actually the result of UV-induced apoptosis (14). Other cells of the skin with critical functions in the homeostasis of the skin, such as epidermal Langerhans cells, are very sensitive to UV-induced apoptosis (15). In addition, inflammation causes neutrophil infiltration, which contributes to physical damage due to secretion of ROS and pro-inflammatory cytokines (16).
- iii. **Ultraviolet damage to DNA.** The heterocyclic bases of the DNA make up the major UVB-absorber chromophore present in skin. Such absorption results in DNA damage due to the formation of pyrimidine dimers (mainly thymine-thymine) and pyrimidine-pyrimidone photo-products (17, 18). These products have been proposed as initial steps in mutagenesis and tumor formation (19). In addition, DNA damage has been linked to systemic immunosuppression (20).
- iv. **Immunosuppression.** UV light causes a wide array of immunosuppressive responses, including the transition from immunologically competent to tolerogenic Langerhans cells, which results in clonal anergy of Th1 cells (21).

In summary, UV irradiation on the skin results in immediate burns, inflammation and local immunosuppression, as well as long-term effects such as premature aging and tumor development. These facts reinforce the need for the development of photoprotective measures. Such investigations are currently following two routes: the development of progressively more efficient sunscreens and of nontoxic substances that can fight the deleterious effects of UV irradiation. *P. leucotomos* lies in both categories, providing sunscreen

protection through the presence of efficient UV blockers in its formulation, and also inhibiting some of the molecular mechanisms that cause UV-induced damage in skin.

***P. leucotomos*: Molecular composition and pharmacology**

The fact that *P. leucotomos* is a natural extract from fern leaves prevents the analysis of its minute composition. However, mass spectrometric analysis revealed that its main constituents are monosaccharides (mainly fructose and glucose); quinic, shikimic, glucuronic and malic acids; and a high proportion of phenolics (22). Most of these phenolics belong to the family of benzoates and cinnamates. These nonflavonoid catecholic compounds have anti-inflammatory, antimutagenic and anticarcinogenic properties (23–26). These effects rely on their intrinsic antioxidant capability (27). Some of them (caffeic and ferulic acids) are naturally conjugated to the saccharidic moiety of *P. leucotomos*, which provides additional stability (28). Caffeic and ferulic acids prevent UV-mediated peroxidation by inhibiting propagation of the lipid peroxidative chain reaction, and also react with nitrogen oxides (29). In addition, ferulic acid is a strong UV photon absorber (30). Both caffeic and ferulic acids are effective in protecting human skin from UVB-induced erythema and are thus employed in the chemical formulation of different skin lotions and sunscreens (31).

Dose-response and kinetics experiments revealed that these phenolics were readily absorbed and completely metabolized 24 hours postingestion. Absorption of most of these compounds is very efficient (70–100%). We found that coumaric, ferulic and vanillic acids were metabolized efficiently (half-life ~4–6 hours) by CYP450-dependent mono-oxygenases and partially conjugated to glucuronic acid and sulfate (32, 33). Such conjugates appear in serum and thus are active reporters of metabolization and absorption of orally ingested phenolics through the intestinal barrier (34). Due to the readiness of *P. leucotomos* absorption through the skin, it is also used topically with good results (35).

Regarding the toxicity profile of *P. leucotomos*, it has been shown that: i) *P. leucotomos* is not mutagenic, as shown by employment of the Ames test (*in vitro* reverse mutation assay) (36); ii) oral acute toxicity as defined in the Organisation for Economic Co-operation and Development guide-

lines (37) yielded negligible results even at high doses of *P. leucotomos* in both rats and mice ($LD_{50} > 2$ g/kg weight); and ii) repetitive treatment (28 and 90 days) has no long-term toxicity (Escario *et al.*, unpublished results).

Evidence for the photoprotective effect of *P. leucotomos*

Classic studies on this and similar fern extracts attributed antitumoral properties to them (38, 39), although their mechanism of action was never properly investigated. Follow-up studies focused on their anti-inflammatory properties, especially regarding skin-related diseases such as psoriasis (40–42), vitiligo (43) and atopic dermatitis (44). The molecular basis for this anti-inflammatory effect relies at least partially on the immunomodulatory capability of these extracts (see next section).

However, classic references pointed out that the native population from Central and South America also used extracts from these ferns to prevent skin inflammation (2). This suggested that these extracts might exert a photoprotective effect. Proof of *P. leucotomos*-induced photoprotection was reported in 1996, when guinea pigs were exposed to UVB light in the presence of placebo or

topically applied *P. leucotomos*, resulting in almost complete photoprotection. *P. leucotomos* was also efficacious when a smaller group of human volunteers was exposed to limited UVA light in the presence of *P. leucotomos* (45). These results encouraged the authors to extend their findings. A second study with a larger group of human volunteers demonstrated the efficacy of *P. leucotomos* in the prevention of acute sunburn (35). In this study *P. leucotomos* also reduced significantly the phototoxic effects of exposure to sunlight after oral ingestion of psoralens. This would provide a critical advantage in phototherapy protocols used for the treatment of various skin disorders, *i.e.*, psoriasis. Psoralens-UVA therapy is a very successful treatment for psoriasis, but the fact that it can induce skin cancer limits its application, especially in the cases of subjects with skin phototypes I and II, which are prone to redness, irritation and increased photoaging (46–48). In addition, this treatment causes hyperpigmentation, which makes it necessary to increase the dose of UVA light, and thus exacerbates phototoxicity and photoaging (49). Preliminary data suggested that *P. leucotomos* was efficacious in reducing phototoxicity induced by exposure to UV light and coadministration of psoralens (35) (Fig. 1). This was confirmed




Fig. 1. Pictures of one subject. A: Phototoxic reaction 48 hours after exposure to psoralens-UVA (PUVA) alone. B: Phototoxic reaction after 48 hours of psoralens-UVA with *Polypodium leucotomos*. C: Pigmentation reaction four months after exposure, showing skin sites exposed to psoralens-UVA alone on the left side and skin sites exposed to psoralens-UVA with *P. leucotomos* on the right side. Pictures show decreased erythema and pigmentation in *P. leucotomos*-treated skin, indicating that *P. leucotomos* decreases the phototoxic and pigmentary response. D: Schematic representation of skin sites in the pictures. Numbers in squares indicate relative UVA intensities of each site (1 = lowest UVA intensity, 6 = highest UVA intensity). Sites exposed to psoralens-UVA without and with *P. leucotomos* are mirrored. Reproduced from ref. 51 with permission from Elsevier, Inc. © 2004.

in an open-label study aimed to determine the beneficial effect of the coadministration of *P. leucotomos* in subjects undergoing psoralens-UVA therapy (50). Orally administered *P. leucotomos* greatly decreased sunburn and mast cell infiltration in the skin, and reduced the loss of epithelial Langerhans cells of the skin associated to these treatments (51). These results together with the lack of toxic effects strongly support the use of *P. leucotomos* as a cotreatment during psoralens-UVA therapy and other phototherapy protocols.

The clinical value of *P. leucotomos* correlates with its histological effect on skin. *P. leucotomos* consistently decreased UV-induced histological damage, characterized by maturation disarray, microvesiculation and keratinocyte vacuolization. Compared to control (UV-irradiated skin), *P. leucotomos*-treated and irradiated skin showed fewer sunburn cells; decreased levels of cyclobutane pyrimidine dimers (an indicator of UV-induced DNA damage) and epidermal cell proliferation, as well as decreased numbers of infiltrating mast cells and neutrophils (52, 53) (Fig. 2).

Other research has aimed to study the photoprotective effect of *P. leucotomos* *in vitro*. In one of these studies, *P. leucotomos* efficiently blocked UVA-induced fibroblast and keratinocyte cell death, and restored proliferation. At the cellular level, *P. leucotomos* inhibited the disorganization of the actin cytoskeleton and adhesive cell-cell and cell-matrix contacts induced by UV light (54). *P. leucotomos* also inhibited protease secretion induced by UV irradiation, and improved the integrity of the membranes of irradiated cells (55). Together, these *in vitro* studies complement the *in vivo* and clinical findings, and demonstrate that the photoprotective effect of *P. leucotomos* occurs at both cellular and systemic levels.

It seems that the photoprotective effects of *P. leucotomos* and similar extracts are related to their anticarcinogenic properties. At the molecular level, *P. leucotomos* has been shown to inhibit UV-induced damage to DNA (53), which is a long-term risk factor in skin cancer (56). Consistent with this, *P. leucotomos* inhibited the appearance of skin tumors after irradiation with UVB light in hairless albino mice (57).

Together, these reports strongly support the photoprotective role of *P. leucotomos* and justify its employment in sunscreen lotions, ointments and even as a complementary oral supplement, as well as its use as a cotreatment in phototherapy. The

oral commercial formulation of *P. leucotomos* (*Heliocare*[®]; IFC S.A., Madrid, Spain, and Baker Cummins Dermatologicals, Miami, FL, USA) has been recently approved for distribution in the United States, and whereas it is not a substitute for sunscreens, it prevents sunburns and limits the damage caused by exposure to UV radiation, adventing a new generation of oral compounds aimed to complement the use of sunscreen formulations. As such, it has been welcomed by both the scientific community and the general public.

Molecular basis of photoprotection

As seen in the previous section, the photoprotective effects of *P. leucotomos* are well documented in different *in vivo* and *in vitro* systems. In this section, we outline the mechanisms by which *P. leucotomos* induces photoprotection and prevents photoaging (Table II).

- i. Direct antioxidant activity. *P. leucotomos* contains a moiety of nonflavonoid phenolics with proven antioxidant activity, especially members of the hydroxycinnamic acid family (32). These prevent UV-mediated peroxidation by inhibiting propagation of the lipid peroxidative chain reaction (29). In addition, *P. leucotomos* can scavenge ROS, a causal agent of aging and various diseases, including cancer, heart disease and autoimmune disorders (58–61). In a free radical scavenging study, *P. leucotomos* was found to efficiently scavenge different ROS, including superoxide anion ($\cdot\text{O}_2^-$), hydroxyl radicals ($\cdot\text{OH}$), singlet oxygen ($^1\text{O}_2$) and H_2O_2 , however to a lesser extent (62). This is an important feature of *P. leucotomos*. ROS are invariably produced in aerobic environments through different mechanisms, such as electron "leakage" during biological oxidation, the action of flavin dehydrogenases and membrane-associated secretions, and by UV-induced activation of oxygen. Thus, ROS scavenging prevents the deleterious effects of local accumulation of ROS.
- ii. Inhibition of photoisomerization and photodecomposition of *t*-UCA. *t*-UCA is the main byproduct of histidine metabolism, and it is endowed with photoprotective properties and ROS-scavenging capability (63). Absorption of UV photons induces its isomerization to *c*-UCA, thus UV photons do not damage other structures. *P. leucotomos* was shown to inhibit *t*-UCA photoisomerization and the appearance of *c*-UCA in a dose-dependent fashion in the pres-




Fig. 2. Histology from paired biopsies of skin treated with ultraviolet radiation alone (left columns) and with *P. leucotomos* (right columns). *P. Leucotomos*-treated skin shows the following: fewer sunburn cells, maturation disarray, microvesiculation and vacuolization (A); fewer cyclobutane pyrimidine dimers (B); less epidermal proliferation (C); and less dermal mast cell infiltration (D). Reproduced from ref. 53 with permission from Elsevier, Inc. © 2004.

Table II: Beneficial effects of *P. leucotomos*.

| On... | Molecular effects | Short-term effects | Long-term effects | References |
|---|---|--|--|----------------------|
| Generation of free radicals | Inhibits ROS generation | | Relieves photoaging, prevents tumor formation | (32, 62, 75) |
| Generation of other deleterious metabolites | Inhibits <i>t</i> -UCA photoisomerization, photodecomposition | | (Predicted) Relieves immunosuppression and tumor formation | (64) |
| Inflammation | Inhibits cell death and apoptosis | Reduces erythema, sunburn* | Relieves photoaging, prevents tumor formation | (35, 45, 50, 51, 53) |
| DNA damage | Decreases the formation of pyrimidine dimers | Reduces SOS response | (Predicted) Inhibits tumorigenesis | (53) |
| Immunosuppression | Prevents depletion of eLC | (Predicted) Reduces recurrent infections | (Predicted) Inhibits chronic inflammation and cancer | (51, 53, 73, 74) |

*Oral administration of *P. leucotomos* (1,080 mg) increases skin tolerance to sunlight by a factor of 2.81 (48). ROS = reactive oxygen species; UCA = urocanic acid; SOS = the SOS response: the depression of multiple genes encoding DNA repair proteins, leading to more rapid DNA repair and enhanced bacterial survival; eLC = epidermal Langerhans cells.

ence of H₂O₂ (64). In addition, UV photons in the presence of ROS and a catalyst such as TiO₂ lead to the formation of hydroxyl radicals and other ROS, which are responsible for the inactivation of enzymatic systems required for homeostasis of the skin (65–68). This process also generates oxidative breakdown metabolites of *t*-UCA that participate in skin immunosuppression (8, 63, 69, 70). This may be an important side effect of many sunscreen lotions, since TiO₂ is used in formulations. *P. leucotomos* efficiently inhibited the breakdown of *t*-UCA and horseradish peroxidase inactivation when coincubated with TiO₂ and irradiated with UV light (64). Together, these results demonstrate the efficacy of *P. leucotomos* as an inhibitor of UV-induced *t*-UCA photoisomerization and photodecomposition, and also in the prevention of the generation of oxidative metabolites catalyzed by TiO₂.

- iii. **Immunoregulation.** The immunoregulatory effect of *P. leucotomos* and other fern extracts has been thoroughly characterized. *P. leucotomos* modulates inflammation through the control of Th1/Th2 responses and prevents immunosuppression caused by depletion of co-stimulatory cells on the skin. *P. leucotomos* blocks the depletion of Langerhans cells in UV-irradiated skin, a major cause of UV-dependent immunosuppression (51, 53). Depletion of epidermal Langerhans cells by UV irradiation is induced by the combination of direct apoptosis,

inflammation, induction of an aberrant morphology (9) and inhibition of the expression of adhesion molecules required for the migration of epidermal Langerhans cells to the skin (71, 72). *P. leucotomos* not only prevented Langerhans cell depletion but also abolished UV-dependent changes in the morphology of Langerhans cells (63). Similar results were obtained using blood dendritic cells irradiated using a solar simulator. In this system, *P. leucotomos* inhibited dendritic cell apoptosis and restored the secretion of anti-inflammatory cytokines by irradiated dendritic cells (73). In addition, expression of IL-10 and TGF- β induced by *P. leucotomos* may account for limitation of the response of other accessory cells, such as macrophages (74).

Conclusions

Originally described as a natural alternative for the treatment of inflammatory skin disorders such as psoriasis, *P. leucotomos* is a more powerful tool than previously thought. It combines extremely low toxicity with proven beneficial effects, even with oral administration. These include antioxidant properties, the capability to inhibit *t*-UCA photoisomerization (which makes it a very valuable additive in sunscreen formulations), and the ability to block UV-induced apoptosis and DNA photodamage and immunosuppression. It seems clear that *P. leucotomos* is not an alternative to traditional sunscreen use, but it provides a very effective complement for sensitive skin phototypes and adds extra protec-

tion in cases in which exposure to UV radiation cannot be avoided, such as those in UVB phototherapy and psoralens-UVA treatments.

Acknowledgements and disclaimer

The authors wish to thank Dr. Miguel Vicente-Manzanares for editorial preparation of the manuscript. The authors declare that all studies pertaining to *P. leucotomos*, to their knowledge, have been included regardless of the direction of the results, and that the affiliation of the authors to Industrial Farmaceutica Cantabria (IFC) has not influenced their views when preparing this work. This work was partially supported by an IFC research grant. S. Gonzalez is a consultant for IFC.

References

- Hassler, M., Swale, B. Checklist of ferns and fern allies. Available at: <http://homepages.caverock.net.nz/~bj/fern/phlebodium.htm>, 2001.
- Ruiz, H. *Disertaciones sobre la raiz de la Rathania, de la Calaguala y de la China y acerca de la yerba llamada Canchalagua*. Madrid: Fundacion Ciencias de la Salud, Sociedad Estatal Quinto Centenario y Real Jardin Botanico (CSIC); 1992.
- Stolze, R.G. *Ferns and fern allies of Guatemala*. Part II. Polypodiaceae, vol. 6. Field Museum of Natural History, Chicago 1981.
- Kripke, M.L. *Immunological unresponsiveness induced by ultraviolet radiation*. *Immunol Rev* 1984, 80: 87-102.
- Lloyd, S.A. *Stratospheric ozone depletion*. *Lancet* 1993, 342: 1156-8.
- Thiele, J., Elsner, P. (Eds.). *Oxidants and antioxidants in cutaneous biology*. Karger, Basel 2001.
- Wlaschek, M., Tantcheva-Poor, I., Naderi, L. et al. *Solar UV irradiation and dermal photoaging*. *J Photochem Photobiol B* 2001, 63: 41-51.
- Noonan, F.P., De Fabo, E.C. *Immunosuppression by ultraviolet B radiation: Initiation by urocanic acid*. *Immunol Today* 1992, 13: 250-4.
- Kurimoto, I., Streilein, J.W. *Deleterious effects of cis-urocanic acid and UVB radiation on Langerhans cells and on induction of contact hypersensitivity are mediated by tumor necrosis factor- α* . *J Invest Dermatol* 1992, 99: 69S-70.
- Hart, P.H., Grimbaldston, M.A., Swift, G.J., Hosszu, E.K., Finlay-Jones, J.J. *A critical role for dermal mast cells in cis-urocanic acid-induced systemic suppression of contact hypersensitivity responses in mice*. *Photochem Photobiol* 1999, 70: 807-12.
- Logan, G., Wilhelm, D.L. *Vascular permeability changes in inflammation. I. The role of endogenous permeability factors in ultraviolet injury*. *Br J Exp Pathol* 1966, 47: 300-14.
- Black, A.K., Greaves, M.W., Hensby, C.N., Plummer, N.A., Warin, A.P. *The effects of indomethacin on arachidonic acid and prostaglandins e2 and f2alpha levels in human skin 24 h after u.v.B and u.v.C irradiation*. *Br J Clin Pharmacol* 1978, 6: 261-6.
- Deliconstantinos, G., Villiotou, V., Stravrides, J.C. *Release by ultraviolet B (u.v.B) radiation of nitric oxide (NO) from human keratinocytes: A potential role for nitric oxide in erythema production*. *Br J Pharmacol* 1995, 114: 1257-65.
- Godar, D.E. *Preprogrammed and programmed cell death mechanisms of apoptosis: UV-induced immediate and delayed apoptosis*. *Photochem Photobiol* 1996, 63: 825-30.
- Obata, M., Tagami, H. *Alteration in murine epidermal Langerhans cell population by various UV irradiations: Quantitative and morphologic studies on the effects of various wavelengths of monochromatic radiation on Ia-bearing cells*. *J Invest Dermatol* 1985, 84: 139-45.
- Hawk, J.L., Murphy, G.M., Holden, C.A. *The presence of neutrophils in human cutaneous ultraviolet-B inflammation*. *Br J Dermatol* 1988, 118: 27-30.
- Mitchell, D.L., Jen, J., Cleaver, J.E. *Sequence specificity of cyclobutane pyrimidine dimers in DNA treated with solar (ultraviolet B) radiation*. *Nucleic Acids Res* 1992, 20: 225-9.
- Lippke, J.A., Gordon, L.K., Brash, D.E., Haseltine, W.A. *Distribution of UV light-induced damage in a defined sequence of human DNA: Detection of alkaline-sensitive lesions at pyrimidine nucleoside-cytidine sequences*. *Proc Natl Acad Sci USA* 1981, 78: 3388-92.
- Hart, R.W., Setlow, R.B., Woodhead, A.D. *Evidence that pyrimidine dimers in DNA can give rise to tumors*. *Proc Natl Acad Sci USA* 1977, 74: 5574-8.
- Kripke, M.L., Cox, P.A., Alas, L.G., Yarosh, D.B. *Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice*. *Proc Natl Acad Sci USA* 1992, 89: 7516-20.

21. Simon, J.C., Tigelaar, R.E., Bergstresser, P.R., Edelbaum, D., Cruz, P.D. Jr. *Ultraviolet B radiation converts Langerhans cells from immunogenic to tolerogenic antigen-presenting cells. Induction of specific clonal anergy in CD4+ T helper 1 cells.* J Immunol 1991, 146: 485-91.
22. Garcia, F., Pivel, J.P., Guerrero, A. et al. *Phenolic components and antioxidant activity of Fernblock, an aqueous extract of the aerial parts of the fern Polypodium leucotomos.* Methods Find Exp Clin Pharmacol 2006, 28: 157-60.
23. Challis, B.C., Bartlett, C.D. *Possible cocarcinogenic effects of coffee constituents.* Nature 1975, 254: 532-3.
24. Koshihara, Y., Neichi, T., Murota, S., Lao, A., Fujimoto, Y., Tatsuno, T. *Caffeic acid is a selective inhibitor for leukotriene biosynthesis.* Biochim Biophys Acta 1984, 792: 92-7.
25. Tanaka, T., Kojima, T., Kawamori, T., Yoshimi, N., Mori, H. *Chemoprevention of diethylnitrosamine-induced hepatocarcinogenesis by a simple phenolic acid protocatechuic acid in rats.* Cancer Res 1993, 53: 2775-9.
26. Tanaka, T., Kojima, T., Kawamori, T. et al. *Inhibition of 4-nitroquinoline-1-oxide-induced rat tongue carcinogenesis by the naturally occurring plant phenolics caffeic, ellagic, chlorogenic and ferulic acids.* Carcinogenesis 1993, 14: 1321-5.
27. Svobodova, A., Psotova, J., Walterova, D. *Natural phenolics in the prevention of UV-induced skin damage. A review.* Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003, 147: 137-45.
28. Bourne, L.C., Rice-Evans, C. *Bioavailability of ferulic acid.* Biochem Biophys Res Commun 1998, 253: 222-7.
29. Saija, A., Tomaino, A., Lo Cascio, R. et al. *Ferulic and caffeic acids as potential protective agents against photooxidative skin damage.* J Sci Food Agric 1999, 79: 476-80.
30. Graf, E. *Antioxidant potential of ferulic acid.* Free Radic Biol Med 1992, 13: 435-48.
31. Saija, A., Tomaino, A., Trombetta, D. et al. *In vitro and in vivo evaluation of caffeic and ferulic acids as topical photoprotective agents.* Int J Pharm 2000, 199: 39-47.
32. Gombau, L., Garcia, F., Lahoz, A. et al. *Polypodium leucotomos extract: Antioxidant activity and disposition.* Toxicol In Vitro 2006, 20: 464-71.
33. Williamson, G., Day, A.J., Plumb, G.W., Couteau, D. *Human metabolic pathways of dietary flavonoids and cinnamates.* Biochem Soc Trans 2000, 28: 16-22.
34. Azuma, K., Ippoushi, K., Nakayama, M., Ito, H., Higashio, H., Terao, J. *Absorption of chlorogenic acid and caffeic acid in rats after oral administration.* J Agric Food Chem 2000, 48: 5496-500.
35. Gonzalez, S., Pathak, M.A., Cuevas, J., Villarubia, V.G., Fitzpatrick, T.B. *Topical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psolaren-induced phototoxic reactions as well as depletion of Langerhans cells in human skin.* Photodermatol Photoimmunol Photomed 1997, 13: 50-60.
36. Ames, B.N., Lee, F.D., Durston, W.E. *An improved bacterial test system for the detection and classification of mutagens and carcinogens.* Proc Natl Acad Sci USA 1973, 70: 782-6.
37. OECD guidelines. Available at: <http://www.oecd.org>. Accessed May 2007.
38. Horvath, A., Alvarado, F., Szocs, J., de Alvarado, Z.N., Padilla, G. *Metabolic effects of calagualine, an antitumoral saponine of Polypodium leucotomos.* Nature 1967, 214: 1256-8.
39. Creasey, W.A. *Antitumoral activity of the fern Cibotium schiedei.* Nature 1969, 222: 1281-82.
40. Padilla, H.C., Lainez, H., Pacheco, J.A. *A new agent (hydrophilic fraction of polypodium leucotomos) for management of psoriasis.* Int J Dermatol 1974, 13: 276-82.
41. Mercadal Peyri, O., Maesci Cappitanio, F. *Preliminary communication on the treatment of psoriasis with anapsos.* Actas Dermosifiliogr 1981, 72: 65-8.
42. Vasange-Tuominen, M., Perera-Ivarsson, P., Shen, J., Bohlin, L., Rolfsen, W. *The fern Polypodium decumanum, used in the treatment of psoriasis, and its fatty acid constituents as inhibitors of leukotriene B4 formation.* Prostaglandins Leukot Essent Fatty Acids 1994, 50: 279-84.
43. Mohammad, A. *Vitiligo repigmentation with Anapsos (Polypodium leucotomos).* Int J Dermatol 1989, 28: 479.
44. Jimenez, D., Naranjo, R., Doblare, E., Munoz, C., Vargas, J.F. *Anapsos, an antipsoriatic drug,*

- in atopic dermatitis*. Allergol Immunopathol (Madr) 1987, 15: 185-9.
45. Gonzalez, S., Pathak, M.A. *Inhibition of ultraviolet-induced formation of reactive oxygen species, lipid peroxidation, erythema and skin photosensitization by Polypodium leucotomos*. Photodermatol Photoimmunol Photomed 1996, 12: 45-56.
 46. Parrish, J.A., Fitzpatrick, T.B., Tanenbaum, L., Pathak, M.A. *Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light*. N Engl J Med 1974, 291: 1207-11.
 47. Melski, J.W., Tanenbaum, L., Parrish, J.A., Fitzpatrick, T.B., Bleich, H.L. *Oral methoxsalen photochemotherapy for the treatment of psoriasis: A cooperative clinical trial*. J Invest Dermatol 1977, 68: 328-35.
 48. Wolff, K., Honigsmann, H., Gschnait, F., Konrad, K. *Photochemotherapy of psoriasis: Clinical experiences with 152 patients (author's transl)*. Dtsch Med Wochenschr 1975, 100: 2471-7, 1497.
 49. Carraro, C., Pathak, M.A. *Studies on the nature of in vitro and in vivo photosensitization reactions by psoralens and porphyrins*. J Invest Dermatol 1988, 90: 267-75.
 50. De las Heras, M.E., Ledo, E., González, S., Rocamora, A., Ledo, A. *An extract of Polypodium leucotomos (Difur®) as adjuvant to PUVA therapy in the treatment of psoriasis vulgaris*. Rev Med CILAD 1997, 25: 103-7.
 51. Middelkamp-Hup, M.A., Pathak, M.A., Parrado, C. et al. *Orally administered Polypodium leucotomos extract decreases psoralen-UVA-induced phototoxicity, pigmentation, and damage of human skin*. J Am Acad Dermatol 2004, 50: 41-9.
 52. Peak, M.J., Peak, J.G. *Solar-ultraviolet-induced damage to DNA*. Photodermatol 1989, 6: 1-15.
 53. Middelkamp-Hup, M.A., Pathak, M.A., Parrado, C. et al. *Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin*. J Am Acad Dermatol 2004, 51: 910-8.
 54. Alonso-Lebrero, J.L., Domínguez-Jiménez, C., Tejedor, R., Brieva, A., Pivel, J.P. *Photoprotective properties of a hydrophilic extract of the fern Polypodium leucotomos on human skin cells*. J Photochem Photobiol B 2003, 70: 31-7.
 55. Phillips, N., Smith, J., Keller, T., Gonzalez, S. *Predominant effects of Polypodium leucotomos on membrane integrity, lipid peroxidation, and expression of elastin and matrix metalloproteinase-1 in ultraviolet radiation exposed fibroblasts, and keratinocytes*. J Dermatol Sci 2003, 32: 1-9.
 56. Trautinger, F. *Mechanisms of photodamage of the skin and its functional consequences for skin ageing*. Clin Exp Dermatol 2001, 26: 573-7.
 57. Alcaraz, M.V., Pathak, M.A., Rius, F., Kollias, N., González, S. *An extract of Polypodium leucotomos appears to minimize certain photoaging changes in a hairless albino mouse animal model*. Photodermatol Photoimmunol Photomed 1999, 15: 120-6.
 58. Valko, M., Rhodes, C.J., Moncol, J., Izakovic, M., Mazur, M. *Free radicals, metals and antioxidants in oxidative stress-induced cancer*. Chem Biol Interact 2006, 160: 1-40.
 59. Finkel, T. *Oxidant signals and oxidative stress*. Curr Opin Cell Biol 2003, 15: 247-54.
 60. Elahi, M.M., Matata, B.M. *Free radicals in blood: Evolving concepts in the mechanism of ischemic heart disease*. Arch Biochem Biophys 2006, 450: 78-88.
 61. Gilgun-Sherki, Y., Melamed, E., Offen, D. *The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy*. J Neurol 2004, 251: 261-8.
 62. Gomes, A.J., Lunardi, C.N., Gonzalez, S., Tedesco, A.C. *The antioxidant action of Polypodium leucotomos extract and kojic acid: Reactions with reactive oxygen species*. Braz J Med Biol Res 2001, 34: 1487-94.
 63. Noonan, F.P., De Fabo, E.C., Morrison, H. *Cis-urocanic acid, a product formed by ultraviolet B irradiation of the skin, initiates an antigen presentation defect in splenic dendritic cells in vivo*. J Invest Dermatol 1988, 90: 92-9.
 64. Capote, R., Alonso-Lebrero, J.L., Garcia, F., Brieva, A., Pivel, J.P., Gonzalez, S. *Polypodium leucotomos extract inhibits trans-urocanic acid photoisomerization and photodecomposition*. J Photochem Photobiol B 2006, 82: 173-9.
 65. Kammeyer, A., Eggelte, T.A., Overmars, H., Bootsma, A., Bos, J.D., Teunissen, M.B. *Oxidative breakdown and conversion of urocanic acid isomers by hydroxyl radical generating systems*. Biochim Biophys Acta 2001, 1526: 277-85.

66. Konaka, R., Kasahara, E., Dunlap, W.C., Yamamoto, Y., Chien, K.C., Inoue, M. *Ultra-violet irradiation of titanium dioxide in aqueous dispersion generates singlet oxygen*. Redox Rep 2001, 6: 319-25.
67. Xu, S., Shen, J., Chen, S., Zhang, M., Shen, T. *Active oxygen species (1O_2 , $O_2^{\cdot-}$) generation in the system of TiO₂ colloid sensitized by hypocrellin B*. J Photochem Photobiol B 2002, 67: 64-70.
68. Dunford, R., Salinaro, A., Cai, L. et al. *Chemical oxidation and DNA damage catalysed by inorganic sunscreen ingredients*. FEBS Lett 1997, 418: 87-90.
69. Harriott-Smith, T.G., Halliday, W.J. *Suppression of contact hypersensitivity by short-term ultraviolet irradiation: II. The role of urocanic acid*. Clin Exp Immunol 1988, 72: 174-7.
70. Norval, M., McIntyre, C.R., Simpson, T.J., Howie, S.E., Bardshiri, E. *Quantification of urocanic acid isomers in murine skin during development and after irradiation with UVB light*. Photodermatol 1988, 5:179-86.
71. Richters, C.D., Reits, E.A., Van Pelt, A.M. et al. *Effect of low dose UVB irradiation on the migratory properties and functional capacities of human skin dendritic cells*. Clin Exp Immunol 1996, 104: 191-7.
72. Rattis, F.M., Concha, M., Dalbiez-Gauthier, C., Courtellemont, P., Schmitt, D., Peguet-Navarro, J. *Effects of ultraviolet B radiation on human Langerhans cells: Functional alteration of CD86 upregulation and induction of apoptotic cell death*. J Invest Dermatol 1998, 111: 373-9.
73. de la Fuente, H., Tejedor, R., Garcia-Lopez, M.A. et al. *Polypodium leucotomos induces protection of UV-induced apoptosis in human skin cells*. The Society of Investigative Dermatology, 66th Annual Meeting, St. Louis, 2005; J Invest Dermatol 2005: A1-A152.
74. Gonzalez, S., Alcaraz, M.V., Cuevas, J. et al. *An extract of the fern Polypodium leucotomos (Difur) modulates Th1/Th2 cytokines balance in vitro and appears to exhibit anti-angiogenic activities in vivo: Pathogenic relationships and therapeutic implications*. Anticancer Res 2000, 20: 1567-75.
75. Gonzalez, S., Joshi, P.C., Pathak, M.A. *Polypodium leucotomos extract as an antioxidant agent in the therapy of skin disorders*. J Invest Dermatol 1994, 102: 651-9.